Associated Genetic Biomarkers
MAGEA8 is altered in 1.32% of all cancers with breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in MAGEA8 are MAGEA8 Amplification (0.07%) and MAGEA8 Loss (0.00%) .
MAGEA8 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains MAGEA8 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with MAGEA8 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is MAGEA8 Expression .
Ima201, cyclophosphamide, fludarabine, and recombinant interleukin-2 are the most frequent therapies in trials with MAGEA8 as an inclusion criteria .
Significance of MAGEA8 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.